Although the European Union has marked solid strides in the way of biosimilars, the overall uptake in individual nations is heavily impacted by domestic policy.
A new paper published in PLOS One details some of the initiatives and regulations affecting biosimilars in the E.U.
The paper also provides some recommendations on how the E.U. can develop a more stable and sustainable market for biosimilars, according to a Center for Biosimilars report.
To read the paper on PLOS One, click here.